Upload Avatar (500 x 500)
Xianjun Qu
Basic Medical Sciences
Capital Medical University
Beijing
Language: Chinese, English
Tumor
Pharmacology
Pathogenesis
Drug Discovery
Cancer
Signaling Pathways
Chronic Colitis
Colon Cancer
Liver Cancer
Metastasis
Areas of Focus
- Tumor Pharmacology
- Tumor Pathogenesis and New Drug Discovery
Work Experience
- Director of the Institute of New Drug Pharmacology at Shandong University
- Director of the Drug Screening Sub-platform of the Shandong New Drug Creation Platform
- Director of the China Office of Drug Discovery Therapeutics and BioScience Trends
Academic Background & Achievements
- Studied at Shandong Medical University and Shandong University
- Director of the Institute of New Drug Pharmacology at Shandong University
- Director of the Drug Screening Sub-platform of the Shandong New Drug Creation Platform
- Director of the China Office of Drug Discovery Therapeutics and BioScience Trends
- Collaborated with universities such as Tokai University, University of Tokyo, University of New South Wales, and University of Bath
- Signed a long-term cancer research cooperation agreement with McGill University
- Principal investigator for 8 major research projects funded by the National Natural Science Foundation
- Received 3 national new drug certificates (anti-gastric cancer drugs)
- Transferred a new drug production license (anti-cancer drug Tegafur, awarded the National Science and Technology Progress Award Second Prize)
Awards
- National Science and Technology Progress Award Second Prize: Anti-cancer drug Tegafur
